XELODA IN BREAST CANCER: THE EXPERIENCE OF LONG-TERM USE
- Authors: Vladimirova L.Y.1, Popova I.L.1, Vladimirova LY.1, Popova IL1
-
Affiliations:
- Issue: No 17 (2011)
- Pages: 62-65
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279055
- ID: 279055
Cite item
Full Text
Abstract
The article presents the retrospective analysis of results of treatment with Xeloda (capecitabine) as monotherapy or in combination with other drugs in 63 patients with metastatic breast cancer (mBC). The data on objective response rate, overall survival and progression-free survival support the view of many authors on the efficacy of Xeloda in patients mBC previously treated with anthracyclines and/or taxanes. The analysis showed that capecitabine is characterized by good tolerability and minimal toxicities.
Keywords
References
- Гарин А.М., Насырова Р.Ю. Капецитабин (Кселода) - удобная лекарственная форма пиримидиновых антиметаболитов, завоевавшая важные позиции на всех этапах лечения рака молочной железы // Эффективная фармакотерапия. Онкология, гематология и радиология, 2011. Т. 2. С. 3-8.
- Переводчикова Н.И., Руководство по химиотерапии опухолевых заболеваний. Практическая медицина, 2011. С. 182-196.
- Ershler WB. Монотерапия капецитабином: эффективное и безопасное лечение метастатического рака молочной железы // Современная онкологи,. 2008. Т. 10. № 1. С. 11-17.
- Hirata M, Tacao S, at al. A phase II trial of oral combination chemotherapy with capecitabine and cyclophosphamide in metastatic breast cancer. Eur J Cancer 2010;8(3):65.
- Martin M. Randomized, phase II trial comparing continuos versus intermittent capecitabine monotherapy for metastatic breast cancer: Results from the GEICAM 2009-05 study..J Clin Oncol 2011;29:82.
- Saif MW, Katirtzoglou NA, Syrigos KN. Капецитабин: клинические проявления и тактика лечения побочных эффектов // Современная онкология, 2008. Т. 10. № 2. С. 22-36.
- Pippen JE, Paul D, at al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide, docetaxel with or without capecitabine in high-risk early breast cancer: Exploratory Ki-67 analyses. J Clin Oncol 2011;29:46.
- Svensson H, Einbeigi Z, at al. Quality of life in women with metastatic breast cancer during nine months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Eur J Cancer 2010;8(3):197.
- Ziellinski C, Gralov J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010;doi:10.1093annoncmdq069:1-8.
Supplementary files
